Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: An Observational Chart Review of a Phase 2 Clinical Trial in Laredo, Texas
Journal: Journal of Case Reports and Studies (JCRS) (Vol.5, No. 2)Publication Date: 2017-04-27
Authors : Soriano RA; Gonzalez M;
Page : 1-7
Keywords : Neumega; Chemotherapy-Induced Thrombocytopoenia; Oprelvekin;
Abstract
This study tested for the cardiac effects of Oprelvekin, recombinant human interleukin-11, a thrombopoietic growth factor, in patients afflicted with chemotherapy-induced thrombocytopenia (platelet count<50,000 cells/ul). Chart-reviews of patients fulfilling the inclusion criteria of: 18-75 yrs of age, non-myeloid malignancy, with adequate hematologic, hepatic and renal parameters and normal electrocardiograms that were enrolled in this phase 2 trial were analyzed. Patients of child-bearing potential agreed to be on a reliable form of birth control for the duration of the study. Results on 4 patients suggest that Oprelvekin does not cause atrial nor ventricular arrhythmia, a rare severe cardiac side effect, in treating patients with chemotherapy-induced thrombocytopenia.
Other Latest Articles
- Judging Credibility of a Road Traffic Accident Claimant
- Methylmalonic Acidemia and Megaloblastic Anemia due to Congenital Intrinsic Factor Deficiency
- Case Reports: Contribution to Clinical Practice, Scholarly Education, and Scientific Knowledge
- A Case Series on Severe Corrosive Injury of Upper Gastrointestinal Tract
- Fracture of the Hamate with Interposition of the Base of 5th Metacarpal, a Frequently Missed Injury
Last modified: 2017-06-23 18:13:52